Peptide Coalition: peptide sequences and trial tags

The names fit on adjacent cards. The experiments often have almost nothing in common.

Stations

Peptide sequence and identity
Trial tags
Approval and sample quality

Peptide sequence and identity

Each discussion starts more sensibly with the chemical identities on the table. Some are fragments, some modified analogues, and one is a sequence-identical synthetic copy. A precise sequence can anchor a literature search; the sequence alone cannot establish a clinical effect or certify a sample.

Member	Sequence or structural identity	Research context
BPC-157	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; molecular formula C62H98N16O22	Synthetic gastric-protein fragment; human evidence reviewed as investigational
CJC-1295	Modified GHRH(1-29), with an albumin-binding handle in the DAC form	Albumin conjugation studied in rats and in vitro; DAC and no-DAC describe different exposure
Semaglutide	Modified GLP-1 analogue with a fatty side chain	Clinical weight-management evidence alongside cardiovascular and kidney trials
Thymosin alpha-1	Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn	Thymalfasin is sequence-identical to the endogenous peptide
PT-141	Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH	Cyclic melanocortin peptide; bremelanotide label

The full BPC-157 sequence discussion separates an identifier from the evidence for a treatment. The distinction matters throughout this collection.

Trial tags

Trial names are useful shorthand once the participants and measured outcomes stay beside them. Here are the tags that recur across the site. The entries deliberately retain the awkward differences.

Trial tag	Who took part	Question and result
ETASS	361 patients with severe sepsis	28-day mortality: 26.0 per cent versus 35.0 per cent; nonstratified P equal to 0.062, log-rank P equal to 0.049
TESTS	1,106 adults with sepsis	No statistically significant 28-day mortality reduction; hazard ratio 0.99, 95 per cent confidence interval 0.77 to 1.27
STEP 1	Adults with overweight or obesity without diabetes	Mean weight change at week 68: minus 14.9 per cent versus minus 2.4 per cent
SELECT	17,604 adults with cardiovascular disease and overweight or obesity without diabetes	Fewer major cardiovascular events; hazard ratio 0.80, 95 per cent confidence interval 0.72 to 0.90
FLOW	3,533 participants with type 2 diabetes and chronic kidney disease	Fewer major kidney-disease events; hazard ratio 0.76, 95 per cent confidence interval 0.66 to 0.88
RECONNECT	1,267 premenopausal women with HSDD across two trials	Improved desire and reduced desire-related distress over 24 weeks

BPC-157's small pilot studies and CJC-1295's early hormone studies have a different place in the record. I resist assigning every member an impressive-looking trial tag just to make the cards match.

Approval and sample quality

BPC-157 and CJC-1295 have no approved human use anywhere and are prohibited at all times in sport. Semaglutide is an approved prescription medicine for several indications. Thymalfasin is approved in more than thirty-five countries and lacks US marketing approval. Bremelanotide has a specific US indication for acquired, generalised HSDD in premenopausal women.

Those histories describe molecules and medicines in regulatory settings. Research-labelled material brings an additional identity and quality question. A compounded preparation has no FDA approval. An approved product's trial cannot verify what a different preparation contains.

A single peptide ranking leaves me arguing about the outcome it has concealed. A weight change, a hormone rise, a desire score and survival after sepsis answer different human concerns. The individual pages let each concern have the space it requires.